{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:22:00Z","timestamp":1781184120032,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T00:00:00Z","timestamp":1301961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>The aim of this prospectively collected, retrospectively analyzed clinical investigation was to describe \u201cunmasked\u201d clinical symptoms and methods of diagnosis, treatment, and short-term follow-up of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) diagnosed during 1 year in Austria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>In total, 277 patients with GEP-NETs were documented. All tumors were immunhistochemically defined according to recently summarized criteria (World Health Organization, European Neuroendocrine Tumour Society). A standardized questionnaire comprising 50 clinical and biochemical parameters (clinical symptoms, mode of diagnosis, treatment, follow-up) was completed by attending physicians.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>The most common initial symptoms were episodes of abdominal pain, diarrhea, weight loss, gastrointestinal bleeding, flushing, and bowel obstruction. Overall, 48.1% of tumors were diagnosed by endoscopy, 43.7% were diagnosed during surgery, 5% were diagnosed by fine-needle aspiration of the primary or metastases, and 2.5% were diagnosed during autopsy; 44.5% of tumors were not suspected clinically and were diagnosed incidentally during various surgical procedures. Overall, 18.7% of tumors were removed endoscopically and 67.6% were removed surgically; 13.7% of patients were followed without interventional treatment. Endoscopic or surgical intervention was curative in 81.4% of patients and palliative in 18.6% of patients. At the time of diagnosis, information on metastasis was available in 83.7% of patients with malignant NETs. Lymph node or distant metastases were documented in 74.7% of patients. In 19.3% of patients, 41 secondary tumors were documented, with 78.0% classified histologically as adenocarcinomas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>This investigation summarizes the clinical presentation and current practice of management of GEP-NETs and thereby extends the understanding and clinical experience.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0002","type":"journal-article","created":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T01:11:17Z","timestamp":1302052277000},"page":"602-613","source":"Crossref","is-referenced-by-count":46,"title":["Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Tumors: Current Data on a Prospectively Collected, Retrospectively Analyzed Clinical Multicenter Investigation"],"prefix":"10.1093","volume":"16","author":[{"given":"Martin B.","family":"Niederle","sequence":"first","affiliation":[{"name":"Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Niederle","sequence":"additional","affiliation":[{"name":"Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,4,5]]},"reference":[{"key":"2021122303334316400_B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1196\/annals.1294.002","article-title":"The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification","volume":"1014","author":"Kl\u00f6ppel","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2021122303334316400_B2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000182196","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification","volume":"90","author":"Kl\u00f6ppel","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1677\/ERC-10-0152","article-title":"Gastroenteropancreatic neuroendocrine tumours: The current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: An analysis based on prospectively collected parameters","volume":"17","author":"Niederle","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2021122303334316400_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-59655-1","volume-title":"Histological Typing of Endocrine Tumours","author":"Solcia","year":"2000","edition":"Second Edition"},{"key":"2021122303334316400_B5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch"},{"key":"2021122303334316400_B6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"2021122303334316400_B7","first-page":"1","volume-title":"WHO Classification of Tumours of the Digestive System","author":"Bosman","year":"2010"},{"key":"2021122303334316400_B8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000098007","article-title":"Well-differentiated gastric tumors\/carcinomas","volume":"84","author":"Ruszniewski","year":"2006","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B9","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s002680010217","article-title":"Is the new classification of neuroendocrine pancreatic tumors of clinical help?","volume":"24","author":"Schindl","year":"2000","journal-title":"World J Surg"},{"key":"2021122303334316400_B10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00268-002-6628-6","article-title":"Treatment of small intestinal neuroendocrine tumors: Is an extended multimodal approach justified?","volume":"26","author":"Schindl","year":"2002","journal-title":"World J Surg"},{"key":"2021122303334316400_B11","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00268-010-0519-z","article-title":"Epidemiology of small bowel carcinoids in a defined population","volume":"34","author":"Landerholm","year":"2010","journal-title":"World J Surg"},{"key":"2021122303334316400_B12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3949\/ccjm.75a.08002","article-title":"Carcinoid tumors: What should increase our suspicion?","volume":"75","author":"Aggarwal","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"2021122303334316400_B13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1196\/annals.1294.025","article-title":"Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center","volume":"1014","author":"Pape","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2021122303334316400_B14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000151562","article-title":"Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France","volume":"89","author":"Lombard-Bohas","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000242109","article-title":"The German NET-registry: An audit on the diagnosis and therapy of neuroendocrine tumors","volume":"90","author":"Ploeckinger","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumors\u2013well-differentiated jejunal-ileal tumor\/carcinoma","volume":"87","author":"Eriksson","year":"2008","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004836-199303000-00009","article-title":"Carcinoid tumors of the gut. Our experience over three decades and review of the literature","volume":"16","author":"Marshall","year":"1993","journal-title":"J Clin Gastroenterol"},{"key":"2021122303334316400_B18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1677\/ERC-07-0221","article-title":"Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors","volume":"15","author":"Halfdanarson","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"2021122303334316400_B19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1634\/theoncologist.2008-0207","article-title":"Carcinoid tumors","volume":"13","author":"Pinchot","year":"2008","journal-title":"The Oncologist"},{"key":"2021122303334316400_B20","first-page":"69","article-title":"The biological relevance of gastric neuroendocrine tumors","volume":"69","author":"Kl\u00f6ppel","year":"1996","journal-title":"Yale J Biol Med"},{"key":"2021122303334316400_B21","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-F","article-title":"Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study","volume":"104","author":"Rindi","year":"1993","journal-title":"Gastroenterology"},{"key":"2021122303334316400_B22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.sla.0000167862.52309.7d","article-title":"Gastric carcinoids: Biologic behavior and prognosis after differentiated treatment in relation to type","volume":"242","author":"Borch","year":"2005","journal-title":"Ann Surg"},{"key":"2021122303334316400_B23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archsurg.136.1.49","article-title":"Treatment of gastric neuroendocrine tumors: The necessity of a type-adapted treatment","volume":"136","author":"Schindl","year":"2001","journal-title":"Arch Surg"},{"key":"2021122303334316400_B24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000085237","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)","volume":"80","author":"Pl\u00f6ckinger","year":"2004","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.5858\/134.6.871","article-title":"Endocrine tumors of the appendix: A pathologic review","volume":"134","author":"Deschamps","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"2021122303334316400_B26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000109876","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumours: Well-differentiated tumour\/carcinoma of the appendix and goblet cell carcinoma","volume":"87","author":"Pl\u00f6ckinger","year":"2008","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000111036","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumours: Well-differentiated colon and rectum tumour\/carcinoma","volume":"87","author":"Ramage","year":"2008","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B28","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s002689900445","article-title":"Stage-dependent therapy of rectal carcinoid tumors","volume":"22","author":"Schindl","year":"1998","journal-title":"W J Surg"},{"key":"2021122303334316400_B29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000109976","article-title":"Poorly-differentiated endocrine carcinomas of midgut and hindgut origin","volume":"87","author":"Ahlman","year":"2008","journal-title":"Neuroendocrinology"},{"key":"2021122303334316400_B30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/jso.21044","article-title":"Multiple primary malignancies in patients with sporadic pancreatic endocrine tumors","volume":"97","author":"Fendrich","year":"2008","journal-title":"J Surg Oncol"},{"key":"2021122303334316400_B31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/1096-9098(200012)75:4<306::AID-JSO14>3.0.CO;2-3","article-title":"Gastrointestinal carcinoid tumors and second primary malignancies","volume":"75","author":"Habal","year":"2000","journal-title":"J Surg Oncol"},{"key":"2021122303334316400_B32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10350-004-6119-y","article-title":"Risk of second cancers in patients with colorectal carcinoids","volume":"45","author":"Tichansky","year":"2002","journal-title":"Dis Colon Rectum"},{"key":"2021122303334316400_B33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/cncr.23159","article-title":"A 35-year retrospective study of carcinoid tumors in Taiwan: Differences in distribution with a high probability of associated second primary malignancies","volume":"112","author":"Li","year":"2008","journal-title":"Cancer"},{"key":"2021122303334316400_B34","first-page":"2413","article-title":"[Neuroendocrine tumors of the gastrointestinal tract (NETGI) and second primary malignancies\u2014which is dominant?]","volume":"128","author":"Brune","year":"2003","journal-title":"Dtsch Med Wochenschr"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0002","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/5\/602\/41854101\/oncolo_16_5_602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/5\/602\/41854101\/oncolo_16_5_602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T06:18:05Z","timestamp":1640240285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/5\/602\/6400843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,5]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,4,5]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0002","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,5,1]]},"published":{"date-parts":[[2011,4,5]]}}}